Stocktoria
NeuroPace Inc NPCE
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-04-22
NeuroPace Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 77.2% | 73.9% | 73.6% | 71.4% | 74.0% |
| Operating margin | -16.3% | -27.1% | -41.5% | -89.6% | -52.5% |
| Net margin | -21.5% | -34.0% | -50.4% | -103.4% | -79.9% |
| FCF margin | -11.3% | -22.8% | -30.4% | -82.3% | -55.2% |
| Return on assets | -20.3% | -28.7% | -30.6% | -41.3% | -27.0% |
| Return on equity | -112.8% | -338.7% | -159.6% | -135.4% | -49.1% |
| Debt / equity | 3.09× | 7.43× | 2.76× | 1.52× | 0.68× |
| Current ratio | 5.28 | 5.37 | 5.71 | 8.90 | 14.28 |
| Revenue growth | 25.1% | 22.1% | 43.7% | 0.7% | 9.8% |
Source: SEC EDGAR filings · CIK 0001528287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.